

2024-2029 Guatemala Infectious Disease Testing Market - Virology, Bacteriology, Parasitology, Mycology - 2024 Supplier Shares, 2024-2029 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations - Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

https://marketpublishers.com/r/222940F73573EN.html

Date: December 2024 Pages: 0 Price: US\$ 1,850.00 (Single User License) ID: 222940F73573EN

Abstracts

This unique report from LeadingMarketResearch.com provides information not available from any other source, including test volume and sales forecasts for 100 individual tests, and competitor strategies. The report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the infectious disease testing market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests; provides test volume estimates by method (molecular,

serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. Rationale

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.



The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Current and Emerging Products

In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.

Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.

Companies developing or marketing infectious disease diagnostic products by individual test.

Opportunities and Strategic Recommendations

Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.

Design criteria for decentralized testing products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new



+357 96 030922 info@marketpublishers.com

products in R&D.



Contents

- I. Introduction
- II. Worldwide Market and Technology Overview
- A. Major Infectious Disease Tests
- 1. AIDS
- 2. ADENOVIRUS
- 3. AEROMONADS
- 4. ANTHRAX/BACILLUS ANTHRACIS
- **5. ARBOVIRUSES**
- 6. BABESIOSIS
- 7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)

and other Bartonella (Rochalimaea)

8. BLASTOCYSTIS HOMINIS

- 9. BRUCELLA
- **10. CAMPYLOBACTER**
- 11. CANDIDA
- **12. CHAGAS DISEASE**
- **13. CHANCROID**

14. CHLAMYDIA

15. CLOSTRIDIUM DIFFICILE



- **16. CORONAVIRUSES**
- **17. COXSACKIEVIRUSES**
- **18. CREUTZFELDT-JAKOB'S DISEASE**
- **19. CRYPTOSPORIDIUM PARVUM**
- **20. CYCLOSPORA CAYETANENSIS**
- 21. CYTOMEGALOVIRUS
- 22. EBOLA VIRUS
- 23. E. COLI
- 24. ECHOVIRUS
- **25. ENCEPHALITIS**
- **26. ENTEROVIRUSES**
- **27. EPSTEIN-BARR VIRUS**
- 28. GIARDIA LAMBLIA
- 29. GONORRHEA
- **30. GRANULOMA INGUINALE**
- **31. HANTAVIRUS**
- **32. HELICOBACTER PYLORI**
- **33. HEPATITIS**
- 34. HERPES SIMPLEX VIRUS

35. HUMAN HERPES VIRUS-6 (HHV-6)



36. INFLUENZA VIRUSES

37. LEGIONELLA

- 39. LYMPHOGRANULOMA VENEREUM (LGV)
- 40. MALARIA
- 41. MEASLES (RUBEOLA)
- **42. MENINGITIS**
- 43. MICROSPORIDIUM
- 44. MONONUCLEOSIS
- 45. MUMPS
- 46. MYCOPLASMA
- **47. PAPILLOMAVIRUSES**
- 48. PARVOVIRUS B19
- **49. PNEUMONIA**
- **50. POLYOMAVIRUSES**
- **51. PSEUDOMONAS AERUGINOSA**
- 52. RABIES
- 53. RESPIRATORY SYNCYTIAL VIRUS (RSV)
- **54. RHINOVIRUSES**
- **55. ROTAVIRUS (REOVIRUS)**



- 56. RUBELLA (MEASLES)
- **57. SALMONELLOSIS**
- **58. SEPTICEMIA**
- **59. SHIGELLOSIS**
- **60. STAPHYLOCOCCUS AUREUS**
- 61. STREPTOCOCCI
- 62. SYPHILIS
- **63. TOXOPLASMOSIS**
- **64. TRICHOMONAS VAGINALIS**
- **65. TUBERCULOSIS**
- 66. VIBRIO

67. WEST NILE VIRUS

68. YERSINA

B. Instrumentation Review: Operating Characteristics,

Features and Selling Princes of Leading Automated

and Semi-automated Analyzers

- C. Emerging Diagnostic Technologies
- III. Market Size, Growth and Sales Forecasts by Test
- IV. Major Product Development Opportunities
- V. Design Criteria for Decentralized Testing Products
- VI. Alternative Market Penetration Strategies
- VII. Distribution Strategies for Decentralized

Testing Markets

- VIII. Potential Market Entry Barriers and Risks
- IX. Competitive Assessments

Abbott



Agilent Technologies Applied Gene Technologies Arca Biopharma Beckman Coulter/Danaher **Becton Dickinson Biokit** bioMerieux **Bio-Rad Decode Genetics Eiken Chemical** Elitech Group Enzo Biochem **Exact Sciences** Fujifilm Wako Fujirebio Grifols Hologic Illumina Leica Biosystems **Li-Cor Biosciences Myriad Genetics** PerkinElmer **Proteome Sciences** Qiagen **Quest Diagnostics** QuidelOrtho Roche Scienion Sequenom/LabCorp Shimadzu **Siemens Healthineers** Sierra Molecular Takara Bio **Tecan Group** Thermo Fisher



I would like to order

Product name: 2024-2029 Guatemala Infectious Disease Testing Market - Virology, Bacteriology, Parasitology, Mycology - 2024 Supplier Shares, 2024-2029 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations - Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

Product link: https://marketpublishers.com/r/222940F73573EN.html

Price: US\$ 1,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/222940F73573EN.html</u>